{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-23-002136","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.068599+00:00","generated_at":"2026-06-10T04:22:34.358225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ImmuCell Q3 preliminary sales $5.4M (+13% YoY); backlog rises to $8.9M","bullets":["Q3 2023 total sales $5.40M, up 13% from $4.80M in Q3 2022.","Nine-month sales $12.38M, down 16% YoY; trailing twelve months $16.29M, down 19%.","Finished goods production in Q3 was $5.3M, approximately 89% of the $6M quarterly goal.","Order backlog increased to $8.9M from $8M at June 30, 2023 and $2.5M at Dec 31, 2022.","Company overcame earlier contamination events; third FDA submission for Re-Tain under 6-month review."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-23-002136","json":"https://secwatch.observer/filing/0001013762-23-002136.json","markdown":"https://secwatch.observer/filing/0001013762-23-002136.md","text":"https://secwatch.observer/filing/0001013762-23-002136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/0001013762-23-002136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/ea186386-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:22:34.358225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f7c8579e46b40adb05cfe2e5790602cb240a7c8","claim":"IMMUCELL CORP /DE/ reported quarter ended September 30, 2023 results: revenue $5.40 million.","evidence_excerpt":"September 30, 2023. Preliminary, Unaudited Total Sales Results: 2023 2022 $ Increase ($ Decrease) % Increase (% Decrease) During the Three-Month Periods Ended September 30, $ 5.40 million $ 4.80 million $ 600,000 13 % During the Nine-Month Periods Ended September 30, $ 12.38 million $ 14.66 million $ (2.28 million ) (16 %) During the Trailing Twelve-Month Periods","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000101376223002136/0001013762-23-002136-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.40 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}